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Abstract
Background: Prognosis and optimal treatment strategies of liposarcoma have not been fully defined. The
purpose of this study is to define the distinctive clinical features of liposarcomas by assessing prognostic
factors.
Methods: Between January 1995 and May 2008, 94 liposarcoma patients who underwent surgical
resection with curative intent were reviewed.
Results: Fifty patients (53.2%) presented with well differentiated, 22 (23.4%) myxoid, 15 (16.0%)
dedifferentiated, 5 (5.3%) round cell, and 2 (2.1%) pleomorphic histology. With the median 14 cm sized of
tumor burden, about half of the cases were located in the retroperitoneum (46.8%). Seventy two (76.6%)
patients remained alive with 78.1%, and 67.5% of the 5- and 10-year overall survival (OS) rates,
respectively. Low grade liposarcoma (well differentiated and myxoid) had a significantly prolonged OS and
disease free survival (DFS) with adjuvant radiotherapy when compared with those without adjuvant
radiotherapy (5-year OS, 100% vs 66.3%, P = 0.03; 1-year DFS, 92.9% vs 50.0%, respectively, P = 0.04).
Independent prognostic factors for OS were histologic variant (P = 0.001; HR, 5.1; 95% CI, 2.0 – 12.9),
and margin status (P = 0.005; HR, 4.1; 95% CI, 1.6–10.5). We identified three different risk groups: group
1 (n = 66), no adverse factors; group 2, one or two adverse factors (n = 28). The 5-year OS rate for group
1, and 2 were 91.9%, 45.5%, respectively.
Conclusion: The histologic subtype, and margin status were independently associated with OS, and
adjuvant radiotherapy seems to confer survival benefit in low grade tumors. Our prognostic model for
primary liposarcoma demonstrated distinct three groups of patients with good prognostic discrimination.
Published: 26 June 2009
BMC Cancer 2009, 9:205 doi:10.1186/1471-2407-9-205
Received: 11 November 2008
Accepted: 26 June 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/205
© 2009 Kim et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 8
(page number not for citation purposes)
BMC Cancer 2009, 9:205 http://www.biomedcentral.com/1471-2407/9/205Background
Liposarcoma is the most common histology of soft tissue
sarcoma and accounts for 20% to 30% of all sarcoma in
adults [1-3]. Despite the skeletal and soft tissue are the
most abundant tissue in the human body, soft tissue sar-
coma consists of only 1% of neoplasms. Due to this low
incidence of the soft tissue sarcoma, only a few studies
reported some prognostic factors for liposarcoma, and
optimal treatment strategies and thereby prognoses have
not been fully defined yet [4-8].
Clinical behavior and prognostic features of soft tissue
sarcoma are known to be associated with histology, and
anatomic distribution. Conventionally, low grade lesions
have higher incidence of local recurrence, and high grade
tumors present with higher incidence of local recurrence
and distant metastasis. Although surgical resection also
remains as the primary treatment of all soft tissue sarcoma
[7,9], radiotherapy has been extensively used in the treat-
ment of sarcomas to improve cure rate and patients' qual-
ity of life [10]. However, there are no confirmatory studies
which directly compared preoperative with postoperative
radiotherapy. Among them, ongoing Toronto study
group's trial demonstrated preoperative radiotherapy had
slightly better outcome in terms of morbidity and survival
benefit even the study was underpowered [11]. There is
still much controversy about the indications and appro-
priate dose/timing for perioperative radiotherapy.
Patients with high risk features for recurrence should be
offered of pre- or postoperative treatment to further
improve treatment outcome.
In this study, we analyzed clinicopathologic features and
prognostic factors for the histologically confirmed liposa-
rcoma patients. We further attempted to devise a prognos-
tic model specific for the disease in order to facilitate
decision making in liposarcoma.
Methods
Patients
Between January 1995 and May 2008, a total of 105
patients were diagnosed as liposarcoma by histologic
exams at Samsung Medical Center. This retrospective
study was reviewed and approved by the Samsung Medi-
cal Center institutional review board (Seoul, Korea).
Among them, 94 patients were treated by surgical resec-
tion with curative intent. The other 11 patients were not
available for further analyses along with complete clinical
data due to patients' refusal for surgical resections or refer-
rals after the relapses. Descriptive characteristics for all the
94 patients are listed in Table 1. Liposarcoma was classi-
fied into 5 histologic subgroups based on Evans Classifi-
cation [12]; well-differentiated, myxoid, dedifferentiated,
round, and pleomorphic. No patient had distant metasta-
sis at the time of surgical resection.
Primary sites were categorized into lower extremity, upper
extremity, trunk, retroperitoneum with or without contig-
uous organ resection. A primary site was considered as
upper extremity when it was at or beyond the shoulder
joint, and as lower extremity when it was located in the
groin, thigh, or leg. Retroperitoneal tumors were catego-
rized as with or without contiguous organ resection
(whether any of the following resections were performed:
colon, small bowel, pancreas, spleen, bladder, uterus)
according to the surgical record. Tumor burden was deter-
mined by the maximum diameter of the primary tumor at
the time of surgical resection. The type of surgery was
reviewed from the surgeons' assessment as documented
on the operative report. We analyzed specimen margins
by gross and microscopic examinations in terms of six
dimensions (superior, inferior, medial, lateral, anterior,
and posterior). We defined a clear margin when there was
no tumor at least 1 mm or more from the edge of the
inked specimen. In addition, microscopically positive
margin was defined when there was a tumor within ≤ 1
mm of the edge. Specimen margins were categorized as
clear, microscopically positive, or grossly positive. None
of the patient had received adjuvant chemotherapy.
Thirty-one (33.0%) patients underwent postoperative
external beam radiation therapy. Follow-up data included
recurrence (local or distant metastasis), and vital status
(alive without disease, alive with diseases, dead of other
cause, dead as a result of sarcoma or sarcoma treatment).
Statistics
The primary end point was overall survival (OS), which was
calculated using Kaplan-Meier method. OS was defined
from the date of surgery to date of death related to the dis-
ease or complication. Survival rates were compared for sta-
tistical differences using log-rank test. OS was assessed with
respect to following factors: age (both as a continuous var-
iable and divided at the median), sex, histologic subtype,
presentation status, primary site, tumor burden (both as a
continous variable and divided into two groups), and resec-
tion margin (negative, microscopically positive, grossly
positive). We also analyzed 5- and 10-year OS. Multivariate
analysis was performed using stepwise Cox proportional
hazards regression modeling. P values less than 0.05 were
considered statistically significant and all P values corre-
sponded to two-sided significance tests. The disease free
survival was defined as time from date of surgery to date of
first recurrence for patients with negative or microscopi-
cally positive resection margin.
Results
Patient characteristics
Ninety-four liposarcoma patients who underwent surgical
resection with curative intent were included in the analy-
sis (Tab 1). There were 41 females and 53 males with
median age of 56 years. The median tumor burden was 14Page 2 of 8
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were as follows: well differentiated in 50 patients
(53.2%), myxoid in 22 patients (23.4%), dedifferentiated
15 patients (16.0%), round cell 5 patients (5.3%), and
pleomorphic in 2 patients (2.1%). We classified the histo-
logic grade into two categories according to previous
study [13]. There were 72 patients with low grade (well-
differentiated and myxoid tumors) and 22 patients with
high grade tumors (dedifferentiated, round cell, pleomor-
phic tumors). Fifty patients had negative resection mar-
gins, 32 had microscopically positive margins, and 12 had
grossly positive margins. Nearly half of the tumors were
located in the retroperitoneum; one third of these patients
required resection of contiguous organ other than kidney.
We also analyzed clinical characteristics according to the
histologic grade (low vs high) as shown in Table 1.
Survival analyses
After a median follow-up duration of 48 months (range,
4.5–166.4 months), 72 (76.6%) patients remained alive
and 22 (23.4%) patients died of the disease. The 5- and
10-year overall survival probabilities were 78.1% and
67.5%, respectively (Figure 1).
OS according to histologic subtype is shown in Table 2.
OS was significantly different according to the histologic
subtype (P < 0.001). Histologic subtypes were dichot-
omized into two groups (well-differentiated and myxoid
tumors vs others). The 5-year OS rates for low and high
grade tumors were 86.1%, and 48.6%, respectively. While
patients with microscopically negative and positive mar-
gins had 5-year OS of 88.1% and 75.0%, respectively,
patients with grossly positive margins had a significantly
decreased 5-year OS of 44.0%. For the tumor burden,
patients with tumor diameter less than 10 cm had signifi-
cantly prolonged OS compared to those with greater than
10 cm (P = 0.013). The 5-year OS rates were 100% and
67.3% for patients with tumor diameter less and greater
than 10 cm, respectively. For the primary sites, extremity
site showed the most favorable prognosis (upper extrem-
Table 1: Patient characteristics
Variables No. of patients
Total (n = 94) (%) Low (n = 72) High (n = 22)
Age, Median (range) 56 (20–80) 55 (20–80) 58.5 (24–75)
Gender
Male 53 (56.4%) 42 (58.3%) 11(50.0%)
Female 41 (43.6%) 30 (41.7%) 11(50.0%)
Presentation status
Biopsy 49 (52.1%) 38 (52.8%) 11(50.0%)
No prior biopsy or treatment 20 (21.3%) 17 (23.6%) 3(13.6%)
Prior excision 25 (26.6%) 17 (23.6%) 8(36.4%)
Histologic variant
Well differentiated 50 (53.2%) - -
Myxoid 22 (23.4%) - -
Dedifferentiated 15 (16.0%) - -
Round 5 (5.3%) - -
Pleomorphic 2 (2.1%) - -
Primary site
Retroperitoneum 44 (46.8%) 31(43.0%) 13 (59.1%)
Without contiguous organ resection 32 (34.0%) 23 (31.9%) 9 (40.9%)
With contiguous organ resection 12 (12.8%) 8 (11.1%) 4 (18.2%)
Lower extremity 24 (25.5%) 23 (31.9%) 1(4.5%)
Upper extremity 9 (9.6%) 9 (12.5%) 0 (0)
Trunk 17 (18.1%) 9 (12.5%) 8 (36.4%)
Tumor burden
Median (cm, range) 14 (2–48) 13 (2–45) 15 (2–48)
Margins
Negative margins 50 (53.2%) 42 (58.3%) 8 (36.4%)
Positive micro margins 32 (34.0%) 24 (33.3%) 8 (36.4%)
Positive gross margins 12 (12.8%) 6 (8.3%) 6 (27.3%)
Postoperative radiotherapy for primary disease
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peritoneal tumors demonstrated a reduced 5-year OS rate
of 61.1%. There was no significant difference in terms of
median age (P = 0.25), sex (P = 0.64), and between those
with or without contiguous organ resection (P = 0.19).
For histologic status, 20 (90.9%) and 2 (9.1%) patient of
low grade liposarcoma experienced local recurrence and
distant metastasis, compare to 11 (84.6%) for local recur-
rence and 2 (15.4%) for distant metastasis among high
grade patients. In terms of resection margins, 23 patients
out of 27 patients (85.2%) with negative resection margin
developed local recurrence, meanwhile all the 8 patients
with positive resection margin experienced local recur-
rence.
We also evaluated DFS only in 82 patients with negative
and microscopically positive margins. Among the evalua-
ble 71 patients, 27 patients (38.0%) experienced relapse,
in which 4 (14.8%) distant metastasis and 23 (85.2%)
local recurrences. Thirteen patients had received excision
of recurred lesion for curative intent. The median DFS was
17.6 months (95% confidence interval [CI], 14.5–20.6
months) for all patients. The DFS was significantly differ-
ent according to the histologic subtype (P = 0.049). The
median DFS of low and high grade tumors were 42.4 and
26.8 months, respectively. The 1-year DFS rates for low
and high grade tumors were 83.3%, and 44.4%, respec-
tively. There were not significantly different DFS in terms
of resection margin (P = 0.23), primary site (P = 0.25),
and tumor burden (P = 0.80).
Impact of adjuvant radiotherapy on survival
In all patients, the administration of adjuvant radiother-
apy did not seem to confer survival benefit (P = 0.39). We
further performed subgroup analyses to identify patients
who may benefit most from postoperative adjuvant radi-
otherapy. In low grade liposarcoma (well differentiated,
and myxoid), a subgroup with adjuvant radiotherapy (n =
22) demonstrated significantly prolonged OS when com-
pared with those without adjuvant radiotherapy (n = 50)
(5-year OS, 100% vs 82.7%, respectively, P = 0.03, Figure
2A). In contrast, there was no survival difference between
the adjuvant radiotherapy (+) and (-) group with high
grade liposarcoma (5-year OS, 45.3% vs 43.2%, P = 0.97,
Figure 2B). Of note, there was a trend toward worse local
control rate (22.7% vs 55.6%, P = 0.08) following adju-
vant radiotherapy in high grade tumors when compared
with low grade liposarcomas. However, there was no sig-
nificant difference respect to adjuvant radiotherapy (+)
and (-) group among in patients with negative resection
margins (n = 50, P = 0.42) and micro/macroscopically
positive resection margin (n = 44, P = 0.61).
For DFS, in low grade liposarcoma, patients received adju-
vant radiotherapy (n = 21) demonstrated significantly
prolonged DFS when compared with those without adju-
vant radiotherapy (n = 46) (1-year DFS, 92.9% vs 50.0%,
respectively, P = 0.04). Similary, there was no survival dif-
ference between the adjuvant radiotherapy (+) and (-)
group with high grade liposarcoma (P = 0.67).
Prognostic model for patients treated by surgical resection 
with curative intent
The clinical factors predicting poor survival at univariate
analyses were as follows: histologic variant (high grade, P
< 0.001), status of resection margin (microscopically or
Table 2: Analysis of Histologic Subtypes in 5-Year Overall Survival (OS)
Histologic Variant Total No. of death 5-Year OS (%) P
Well differentiated 50 5 (10%) 93.3 P < 0.001
Myxoid 22 4 (18.2%) 75.7
Dedifferentiated 15 6 (40%) 54.5
Round 5 3 (60%) 40.0
Pleomorphic 2 2 (100%) 0
Overall survival of all patientsFigure 1
Overall survival of all patients.Page 4 of 8
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Overall survival according to adjuvant radiotherapy for patients with low grade sarcomas (A) and high grade liposarcomas (B)Figure 2
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Variables Univariate Multivariate Survival (%)
P HR (95% CI) P 5-year OS
Histologic variant (high vs Low) < 0.001 5.1 (2.0–12.9) 0.001 48.6 vs 86.1
Margin status (positive vs negative) < 0.001 4.1 (1.6–10.5) 0.005 44.0 vs 83.0
Primary site
(trunk or retroperitoneum vs extremity)
0.009 - 0.239 61.1 vs 90.0
Tumor burden (> 10 cm vs ≤ 10 cm) 0.013 - 0.164 67.3 vs 100.0
grossly positive margin, P < 0.001), primary site (retroper-
itoneum or deep trunk, P = 0.009) and tumor burden
(more than 10 cm, P = 0.013). The forward Cox regression
model was used to establish independent prognostic fac-
tors. Independent prognostic factors for survival were his-
tologic variant (P = 0.001; HR, 5.1; 95% CI, 2.0 – 12.9),
and margin status (P = 0.005; HR, 4.1; 95% CI, 1.6–10.5)
as shown in Table 3. All the patients had complete infor-
mation on the two parameters and included in the prog-
nostication. The prognostic grouping was performed
according to the following criteria: group 1 (n = 66), no
adverse factors; group 2, one or two adverse factors (n =
28). The Kaplan-Meier survival curves according to the
prognostic index are shown in Figure 3 (P < 0.001). The
prognostic model separated patients into two risk groups
with significantly different survival outcomes. The 5-year
OS rate for group 1, and 2 were 91.9%, 45.5%, respec-
tively.
Discussion
Liposarcoma is the most common soft tissue sarcoma
which accounts for about 20% of sarcoma in adults [14].
Histologic classification have been well established by the
current World Health Organization, which is almost iden-
tical to the paradigm implemented by Enzinger and Win-
slow [15]. The 5 histologic subgroups of liposarcoma
pursue different natural clinical course not only in terms
of clinical features but also the survival outcome. Never-
theless, current clinical practice is not optimized accord-
ing to different histologic subtypes and clinical protocol
often does not reflect such difference. In this study, we ret-
rospectively analyzed a homogeneous cohort of primary
liposarcoma patients. To improve the risk based stratifica-
tion for treatment, we also attempted to establish a prog-
nostic model for this subset of patients.
In the present study, the most common subtype was well-
differentiated liposarcoma which accounted for approxi-
mately 50% of all cases. The overall survival was well strat-
ified by histologic subtype, which was concordant with
the results from previous studies [13,16]. Multivariate
analyses further demonstrated that histologic subtype was
an independent prognostic factor for survival. High grade
tumors (dedifferentiated, round cell, pleomorphic
tumors) were associated with approximately 5-fold
increased risk of deaths compared with low grade tumors.
The efficacy of radiation therapy to improve local control
has been well reported in the previous randomized trials
of extremity soft tissue sarcomas [17,18]. In contrast to
extremity sarcoma, the role of adjuvant radiotherapy for
patients with retroperitoneal sarcoma is not well clarified.
Some studies revealed that adjuvant radiotherapy reduces
the risk of local recurrence and improves local control
[19,20]. Thereby some patient with negative resection
margin had received adjuvant radiotherapy when primary
tumors are large-sized or deep retroperitoneal origin. The
addition of adjuvant radiotherapy seems to confer sur-
vival benefit in low grade tumors although limited by ret-
rospective nature of the analyses. As illustrated in Figure
2A, the impact of adjuvant radiotherapy on survival was
Overall survival of patients by prognostic modelFigure 3
Overall survival of patients by prognostic model. 
Group 1 (n = 66), no adverse factors; Group 2, one or two 
adverse factors (n = 28).Page 6 of 8
(page number not for citation purposes)
BMC Cancer 2009, 9:205 http://www.biomedcentral.com/1471-2407/9/205more prominent in low grade sarcomas than high grade
tumors. Interestingly, the local control rate was consider-
ably lower in the high grade tumor group when compared
with low grade group following postoperative radiother-
apy (local failure rate 22.7% vs 55.6%, P = 0.08). In sup-
port of this, there were no differences in margin status
between the two groups. In addition, to clarify the benefit
of radiotherapy, we also analyzed significant prognostic
factors for DFS and efficacy of adjuvant radiotherapy for
patients with negative and microscopically positive mar-
gins. The DFS was significantly different according to the
histologic subtype, and patients with low grade liposar-
coma demonstrated better DFS with postoperative adju-
vant radiotherapy. The underlying mechanisms that cause
these changes are uncertain. It is possible that patients
with high grade tumor had slightly more retroperitoneal
site and positive resection margins than those with low
grade. Even though this is the retrospective study with rel-
atively small sample size, we emphasize that these results
should be cautiously interpreted and prompt future pro-
spective studies.
To improve risk-based stratification for therapy, we
attempted to establish a prognostic model specifically
devised for patients treated by surgical resection with cur-
ative intent. At multivariate analyses, histologic variant (P
= 0.001; HR, 5.1; 95% CI, 2.0–12.9), resection margin sta-
tus (P = 0.005; HR, 4.1; 95% CI, 1.6–10.5) retained statis-
tical significance. The prognostic grouping was based on
scoring system of the adverse factors and yielded distinc-
tive sets of two groups with different survival outcome (5-
year OS rates for group 1, and 2 were 91.9%, and 45.5%,
respectively.) Given a poor prognosis of patients with one
or two adverse factors in the model, this subgroup of
patients may potentially benefit from more aggressive
postoperative treatment. Hence, the role of adjuvant
chemotherapy with or without radiotherapy may be stud-
ied in this subgroup of patients. Our prognostic model
demonstrated two groups of patients with distinct prog-
nostic discrimination. More aggressive postoperative
treatment such as combined modalities with chemother-
apy and radiotherapy should be offered in the context of
clinical trials in this particular subgroup of liposarcoma
patients. Nonetheless, prospective study is needed to vali-
date the model on larger population.
In this study, the frequency of retroperitoneal primary site
was high accounting for half of the cohort. Previous stud-
ies in western population demonstrated relatively lower
incidence of retroperitoneal primary site ranging from
25–33.4% of all cases [4,13]. Retroperitoneal tumors usu-
ally presented with large-sized mass and involvement of
multiple contiguous organs and thus, a wide excision with
adequate resection margin may not have been technically
feasible. Its anatomic characteristics may render relatively
poor survival outcome of this study compare to previous
studies which have shown 75% to 83% of 5-year overall
survival.
Conclusion
Histologic subtype, and margin status are independently
associated with disease specific survival, and patients with
low grade histology had benefit from adjuvant radiother-
apy. Proposed model for primary liposarcoma demon-
strated distinct groups of patients with good prognostic
discrimination. The impact of adjuvant radiotherapy on
OS and DFS were more prominent in low grade sarcomas
than high grade tumors. We hope our study may facilitate
further prospective study and alternatively clinical deci-
sion making in liposarcoma, combined with reliable
molecular markers.
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